Weight Changes With Integrase Strand Transfer Inhibitor Therapy in the Management of HIV Infection: A Systematic Review.

E Kelly Hester Sage B Greenlee Spencer H Durham

Published in: The Annals of pharmacotherapy (2022)

Within the INSTI class, dolutegravir and bictegravir may be associated with the greatest risk for weight gain particularly when combined with tenofovir alafenamide. Further research is needed to determine mechanisms for observed weight changes and any contributions to clinically significant metabolic and cardiovascular adverse outcomes associated with INSTI therapy.

Keyphrases

weight gain
body mass index
birth weight
antiretroviral therapy
weight loss
physical activity
stem cells
hiv infected patients
bone marrow